Showing 3011-3020 of 3039 results for "".
- OWL: Advancing Diversity in Leadership Appoints New Executive Director, Gaynor Frieshttps://modernod.com/news/owl-advancing-diversity-in-leadership-appoints-new-executive-director-gaynor-fries/2480180/OWL: Advancing Diversity in Leadership announced that Gaynor Fries has been appointed Executive Director of the organization. Gaynor has been a key part of the support team behind OWL since July 2015. With a BA in Business Administration and a Certificate in Non-Profit Management from Duke
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- Call for Abstracts for Academy 2018 San Antonio Scientific Programhttps://modernod.com/news/call-for-abstracts-for-academy-2018-san-antonio-scientific-program/2480193/The Scientific Program Committee of the American Academy of Optometry invites the submission of abstracts for Academy 2018 San Antonio, to be held Wednesday, November 7 through Saturday, November 10. The Academy’s Scientific Program offers scientists, educators, and clinicians the opportuni
- Aerie Announces US Launch of Rhopressahttps://modernod.com/news/aerie-announces-us-launch-of-rhopressa/2480197/Aerie Pharmaceuticals announced that it has launched Rhopressa in the United States. Rhopressa is now in national and regional US pharmaceutical distributors, and patients have access to Rhopressa through their local pharmacies across the nation. “We are pleased to announce the availabilit
- ThromboGenics Initiates Phase 2 Clinical Study Evaluating Anti-PlGF in Combination With Anti-VEGF for Treatment of DMEhttps://modernod.com/news/thrombogenics-initiates-phase-2-clinical-study-evaluating-anti-plgf-in-combination-with-anti-vegf-for-treatment-of-dme/2480200/ThromboGenics announced that it has successfully enrolled the first patient in a phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis, Novartis), for the treatment of DME (NCT03499223). TH
- Johnson & Johnson Vision Highlights New Data at 2018 ARVO Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-highlights-new-data-at-2018-arvo-annual-meeting/2480201/Johnson & Johnson Vision announced that a suite of new research from its eye health portfolio will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu, Hawaii from April 29 to M
- Hill-Rom Enhances Spot Vision Screener to Serve Senior Populationhttps://modernod.com/news/hill-rom-enhances-spot-vision-screener-to-serve-senior-population/2480205/Hill-Rom announced new enhancements to its Welch Allyn Spot Vision Screener, enabling the device to quickly and effectively screen for vision issues in adult patients with pupil sizes as small as 3 mm, according to a company news release. Spot Vision Screener is a handheld, portable device
- ianTECH’s miLOOP Grabs Two “Best Paper of Session” Wins at the ASCRS-ASOA Annual Meetinghttps://modernod.com/news/iantechs-miloop-grabs-two-best-paper-of-session-wins-at-the-ascrs-asoa-annual-meeting/2480210/Two presentations among the several featuring ianTECH’s novel »miLOOP Device won “Best Paper in Session” awards during the 2018 meeting of the American Society of Catarac
- Congressional Briefing Discussing Safety of Contact Lenses as Regulated Medical Devices to be Held Tomorrowhttps://modernod.com/news/congressional-briefing-discussing-safety-of-contact-lenses-as-regulated-medical-devices-to-be-held-tomorrow/2480218/The Health Care Alliance for Patient Safety will hold a congressional briefing tomorrow, Tuesday, April 24, 2018, from noon-1 pm in The Rayburn House Office Building, Room 2247, in Washington DC, to discuss the importance of protecting the safety of patients who use contact lenses, which are regu
- Data from BioTime’s OpRegen and Retinal Restoration Programs to Be Presented at ARVO 2018https://modernod.com/news/data-from-biotimes-opregen-and-retinal-restoration-programs-to-be-presented-at-arvo-2018/2480231/BioTime announced that data from the ongoing OpRegen clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29 – May 3, 2018, in Honolulu, Hawaii. The scheduled times (note